Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of ABBV-552 in healthy male volunteers
NCT06278766Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SDI-118 in Alzheimer's disease (AD), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events (AEs) at 30 days, Maximum observed concentration (Cmax) of ABBV-552 at Day 15 and 10 more. Started Feb 2024; status: completed.
02
Drugs
SDI-118
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06278766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06278766.